KRT14 and breast cancer: Furthermore, the proportion of KRT14+ LCs is significantly enriched in breast cancer micro-metastatic tumours compared to relatively low numbers observed in the primary tumour and established secondary metastases (43–67% vs. 0.9% and 2.5%, respectively) [65].